The Molecular Imaging Laboratory, which is part of the Sloan Kettering Institute’s Molecular Pharmacology Program, is focused on both the development of new molecular probes for cross-sectional, multimodality imaging (MRI, PET and optical) and translational research in molecular imaging. This ranges from basic science to clinical translation, as well as clinical molecular imaging observations to basic science tumor analysis. The objective of the research is to further improve our understanding of in vivo tumor biology and interaction with its microenvironment, with the ultimate goal of early tumor detection and characterization and the development of imaging as a prognostic, predictive, and early-response biomarker.
Hedvig Hricak, MD, PhD
Chair, Department of Radiology
Research FocusRadiologist Hedvig Hricak researches methodologies of molecular imaging of prostate and gynecologic tumors.
- MD, University of Zagreb School of Medicine (Yugoslavia)
- Dr. Med. Sc. Karolinska Institute (Sweden)
- Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, Ivanova A, Ageyeva L, Tourkova V, Balatoni J, Bornmann W, Blasberg R, Gelovani Tjuvajev J. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51.
- Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy.Radiology. 2005 Mar;234(3):804-14.